RxDoctor Payments Data

Daniel Chiu

Gerontology · Orange, CANPI 1427419530

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.4% of the total across 902 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 39 manufacturers reported payments, led by AbbVie at 29.7% of the total. Among gerontology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,652in general payments, 2019–2025

Across 902 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Johnson & Johnson$1K
  • QOL Medical, LLC$731
  • Madrigal Pharmaceuticals$602
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$16,55199%
  • Education$1011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,652 in reported general payments places this provider in the 95th percentile of 348 gerontology providers in California.

See all gerontology providers in California

Medicare billing

Part B allowed, 2024
$75,722
Medicare patients
428
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin113$334,274
ZenpepLipase/Protease/Amylase19$97,581
Humira(Cf) PenAdalimumab11$77,139
LinzessLinaclotide67$71,173
CreonLipase/Protease/Amylase11$36,570
Mesalamine39$23,526
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates259$14,851
Omeprazole470$9,924
Pantoprazole Sodium505$8,176
Entecavir19$5,019
Ursodiol18$4,303
Lubiprostone22$3,541
Sucralfate61$3,016
Lactulose43$2,637
Famotidine108$2,130

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,822$334,274113 claims
AbbVieLinzess, Creon$4,953$107,74378 claims
Aimmune Therapeutics, Inc.Zenpep$336$97,58119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 gerontology providers in California.

Other gerontology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →